February 10, 2020 / 2:30 PM / 18 days ago

BRIEF-U.S. FDA Grants Priority Review For Kite's KTE-X19 Biologics License Application

Feb 10 (Reuters) - Gilead Sciences Inc:

* U.S. FDA GRANTS PRIORITY REVIEW FOR KITE’S KTE-X19 BIOLOGICS LICENSE APPLICATION (BLA) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

* GILEAD SCIENCES INC - PDUFA OR TARGET ACTION DATE IS AUGUST 10, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below